Geralgine

Quick links to important sections

Geralgine

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Geralgine

Property Description
Active ingredient Paracetamol (Acetaminophen)
Form Oral Solid, Oral Liquid, Rectal, Parenteral
Pharmacological class Non-Opioid Analgesic, Antipyretic
General purpose Relief of pain and reduction of fever
Origin Synthetic chemical compound

Geralgine represents a widely recognized medicinal entity whose active ingredient is Paracetamol, officially known by the INN Acetaminophen (APAP) and the chemical entity N-acetyl-p-aminophenol. This compound is clinically recognized for its reliable efficacy in managing common discomfort. It is classified pharmacologically as a non-opioid analgesic and an antipyretic, utilized for managing discomfort and reducing elevated body temperature. This classification is key because Geralgine’s effects are chiefly mediated by actions within the central nervous system, a characteristic that differentiates it from the peripheral action of anti-inflammatory drugs.

The medicine is defined by its single-active-ingredient composition, based solely on the pure, synthetic chemical entity, Paracetamol. The preparation is available in various dosage forms, including oral solid preparations (tablets and capsules), oral liquid preparations (suspensions), and specialized parenteral preparations (intravenous solutions), which use an inert excipient matrix or aqueous solvent base appropriate for the chosen route of administration. Geralgine, like other formulations of this compound, is frequently positioned as an accessible Over-the-Counter (OTC) option designed for general patient groups, including both adults and children.

The general purpose of Geralgine is to provide relief from aches and minor pains and to effectively reduce elevated body temperature. The designation of Paracetamol as an essential medicine highlights the drug’s fundamental reliability and importance as a core option for symptom management globally. This benefit is achieved through its primary physiological principles: the capacity to elevate the body’s overall pain threshold and influence the central thermoregulatory center when fever is present.

Regulatory References

  1. Acetaminophen - StatPearls - NCBI Bookshelf
  2. WHO Model List of Essential Medicines
  3. Paracetamol (acetaminophen) on eEML

What side effects are possible with Geralgine?

Possible Side Effects and Safety Information

The official safety profile for Geralgine (Paracetamol/Acetaminophen) is structured by government regulatory agencies around the risk of specific physiological events, classified by frequency and affected organ system. This information is descriptive and does not constitute medical advice.

Adverse Reactions and Frequencies

Adverse reactions documented in regulatory sources are predominantly classified as Rare or Very Rare when the medicine is used within therapeutic limits. Few effects are consistently classified as Common. Potential adverse reactions are formally grouped into affected System-Organ Classes (SOCs):

  • Hepatobiliary Disorders: The primary safety concern is the risk of Hepatotoxicity (liver damage), which is strongly associated with exceeding the maximum daily dose.
  • Blood and Lymphatic System Disorders: Rare and Very Rare effects include severe blood dyscrasias, such as thrombocytopenia (low platelet count) and agranulocytosis (very low white blood cell count).
  • Immune System Disorders: Covers hypersensitivity reactions, which can include the very rare occurrence of anaphylactic shock.
  • Skin and Subcutaneous Tissue Disorders: Includes rash and urticaria, as well as the very rare but serious cutaneous adverse reactions (SJS, TEN, AGEP).

Safety Constraints and Considerations

The most significant safety constraint explicitly documented by regulators concerns exposure and pre-existing conditions:

  • Serious Adverse Reactions: Severe liver damage is the principal risk, occurring with acute overdose or chronic misuse (ingesting doses above the maximum daily threshold over time).
  • Population-Specific Caution: Caution is advised, and use may be contraindicated, in patients with severe hepatic impairment, severe renal impairment, or chronic alcoholism, as these factors increase the risk of severe toxicity.
  • Co-administration: Official documents restrict the concurrent use of Geralgine with any other product containing Paracetamol/Acetaminophen to prevent accidental over-exposure.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Official regulatory documents define the Geralgine (Paracetamol) overdose profile primarily by the risk of delayed, severe hepatotoxicity. Initial, non-specific manifestations of an overdose may include nausea, vomiting, diaphoresis (sweating), and general malaise. Crucially, these initial symptoms may be followed by a latent period before the development of severe toxicity. The most serious officially documented outcome is Acute Hepatic Failure, which can progress to hepatic necrosis, encephalopathy, and subsequent death. Coagulopathy and acute renal tubular necrosis are also noted complications.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose, irrespective of whether the patient currently exhibits symptoms. Regulatory guidance mandates that emergency medical services or a poison control center must be contacted immediately for management advice. The specific antidote for paracetamol toxicity, N-acetylcysteine (NAC), is identified in official labeling, and its urgent administration is necessary to mitigate potential liver injury.

Monitoring and Risk Considerations

Continuous hospital monitoring and observation are mandated for all overdose cases to track serum concentrations and essential laboratory parameters, including liver function tests. Regulatory texts note an increased risk of severe hepatotoxicity in individuals with pre-existing hepatic impairment, chronic alcohol use, or states of severe nutritional deficiency.

Therapeutic Uses of Geralgine

What Geralgine Treats: Main Uses and Benefits

Geralgine (Paracetamol) is an analgesic and antipyretic commonly used to address symptoms related to physical discomfort and systemic imbalance. The medication is applied across therapeutic domains where short-term symptomatic assistance is appropriate for addressing symptoms that create noticeable physiological strain.

It is relevant for easing mild to moderate acute pain presentations, including headache, muscle aches, toothache, and discomfort associated with primary dysmenorrhea. It is also applied in conditions marked by heightened physiological activity, specifically for the symptomatic relief of fever and the generalized malaise related to colds, flu, or post-vaccination reactions. This offers symptomatic relief that **may help patients cope more steadily with symptom fluctuations.

“It is commonly used when short-term symptomatic assistance is needed for pain and fever in diverse patient groups.”


Quick Fact: Relief for Acute Symptom Episodes

Geralgine is considered relevant when supportive symptom management is appropriate, provides support that helps ease the overall symptom burden during phases of increased distress.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for Geralgine is strictly defined by regulatory bodies based on age, physiological status, and the presence of contraindicating conditions.

Populations for Whom Use is Prohibited or Restricted

Status Population Group (Official Labeling)
Contraindicated Patients with known hypersensitivity to Paracetamol or any excipient [Source 1.3]. Patients with severe active liver disease or severe hepatic impairment [Source 1.1, 1.5].
Conditional Use/Caution Individuals with severe renal impairment or mild to moderate hepatic impairment [Source 1.1]. Patients with chronic alcoholism or chronic malnutrition due to increased hepatotoxicity risk [Source 1.4].

Age-Group and Physiological Eligibility

  • Adults and Adolescents: Fully eligible for use under standard labeled conditions [Source 1.2].
  • Pediatric Population: Use is permitted but strictly governed by weight-based dosage and formulation, with specific products not recommended for children below certain age thresholds (e.g., standard tablets not for children under 12 years) [Source 1.4].
  • Pregnancy and Lactation: Geralgine is widely considered a permitted option when clinically necessary [Source 4.2]. Regulatory guidance emphasizes using the lowest effective dose for the shortest duration [Source 4.5]. It is also permitted while breastfeeding, as published data do not contraindicate it [Source 4.2].

What should I know about interactions with other medicines?

Geralgine Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Geralgine (Paracetamol/Acetaminophen), based strictly on government regulatory information.

Formal Interaction Constraints

The primary restriction cited across regulatory documents is the prohibition of co-administration with any other medicine containing acetaminophen. This is a critical instruction intended to prevent acute liver toxicity resulting from exceeding the maximum safe daily dose.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interactions primarily involve altered absorption, changes in metabolism, or an enhanced effect on co-administered drugs.

Interaction Type Interacting Substance/Class Official Regulatory Statement
Metabolic Risk Hepatic Enzyme Inducers (e.g., Carbamazepine, Phenytoin) Concomitant use may increase hepatotoxic potential due to altered metabolism.
Absorption Rate Metoclopramide or Domperidone Increases the rate and extent of Geralgine absorption.
Absorption Reduction Cholestyramine Reduces absorption; dose separation of at least one hour is advised.
Pharmacodynamic Oral Anticoagulants (e.g., Warfarin) Prolonged, regular use can enhance the anticoagulant effect, requiring closer International Normalized Ratio (INR) monitoring.

Population and Product-Specific Cautions

Official labels note that the risk of severe liver damage is higher in individuals with chronic, excessive alcohol consumption. Furthermore, the co-administration of Flucloxacillin has been associated with High Anion Gap Metabolic Acidosis (HAGMA), particularly in patients with existing risk factors for glutathione depletion.

Mechanism of Action

Central COX Inhibition and Thermoregulation

The drug's core mechanism is the selective, reversible inhibition of Cyclooxygenase-2 ( COX-2) activity, primarily within the Central Nervous System ( CNS). By reducing the production of Prostaglandin E2 ( PGE2) in the hypothalamus, the drug initiates a cascade that resets an abnormally elevated thermoregulatory set point, which subsequently leads to heat dissipation.

Dual Action on Spinal and Supraspinal Nociception

Geralgine engages two distinct mechanisms to modulate nociceptive signals. It reduces PGE2-mediated sensitization of pain pathways and, through its metabolite AM404, activates TRPV1 receptors and inhibits the reuptake of Anandamide ( AEA). These complementary actions enhance the body's descending inhibitory signaling, effectively raising the nociceptive threshold.

Mechanistic Limitations: Peroxide Sensitivity

The drug exhibits a unique hydroperoxide-sensitivity constraint on its COX-inhibitory action, resulting in limited functional inhibition within the high hydroperoxide environment of peripheral tissues. This mechanism ensures that the drug's activity is focused on CNS processes rather than mediating widespread peripheral anti-inflammatory changes.

Dosage and Administration Information

How Geralgine is Used

Geralgine (Paracetamol) is indicated for administration via oral (tablets, solutions), rectal (suppositories), and intravenous (IV) infusion routes. The usage pattern is intermittent and based on minimum time intervals to maintain the total dose within established limits. Oral forms may be administered with or without food.

Official Administration Rules

Parameter Adult Dosing Regimen (ge 50 kg)
Single Dose 650 mg every 4 hours or 1000 mg every 6 hours
Max Single Dose 1000 mg
Min Dosing Interval 4 hours
Max Daily Dose (All Routes) 4000 mg (4 grams)

All doses must be strictly managed to ensure the maximum total daily intake from all sources (oral, rectal, and IV) does not exceed 4000 mg.

Specialized Use and Administration

Intravenous Infusion requires precise procedural steps, including administering the dose over a controlled 15-minute period. For lower, weight-based doses, the amount must be accurately withdrawn and transferred to a separate container prior to infusion. The dosing for pediatric patients is calculated based on body weight (e.g., 15 mg/kg every 6 hours for children 2 to 12 years of age).

Population-Specific Adjustments are mandatory for certain patients. For those with severe kidney or liver impairment, guidance mandates a dose reduction or a prolonged dosing interval—sometimes to 6 or 8 hours—to accommodate altered clearance. For non-prescription use, the duration should not exceed 10 days for pain or 3 days for fever.

Recent Clinical Evidence

Research evidence / Overview of studies for Geralgine (Paracetamol)

Evidence for Acute Symptom Management: Pain

The regulatory research base for Geralgine was studied using randomized controlled trials (RCTs) and comprehensive systematic reviews. These studies were used in research exploring how symptoms change over time and examining patient-reported outcomes describing perceived discomfort. Research examined outcomes related to physical discomfort in conditions associated with acute or disruptive episodes, such as headache, dental pain, and musculoskeletal pain.

Studies reported various patterns observed in the treatment groups, often involving the measurement of pain intensity changes and the duration of symptomatic changes. Systematic reviews reported that the evidence level was generally classified as high for short-term outcomes in certain acute pain scenarios. However, the available data show patterns related to modest or limited observed symptomatic changes in other conditions where symptoms may vary in intensity, such as chronic pain states. Research describes that for these latter conditions, the evidence quality varies across studies, and many reports are associated with low certainty.


Evidence for Symptomatic Relief of Fever

Geralgine was also studied for its antipyretic properties, which involves examining temporary physiological imbalance. This research utilized short-term RCTs, often comparing it to an inactive placebo, applied in studies examining patient-reported experiences related to systemic or functional imbalance. Studies were conducted during periods of increased symptom activity in both adult and, primarily, pediatric populations experiencing fever related to infection or vaccination.

Studies report how symptoms evolved in the observed populations, specifically focusing on the outcomes related to body temperature reduction and the time it took for the fever to subside. Evidence describes patterns related to temperature-lowering in children that were generally similar across trials. However, studies report that outcomes reflecting daily functioning, beyond the immediate temperature reading, were often limited. Evidence indicates that findings were mixed, and the certainty remains low when examining outcomes related to clinical relevance (such as reduced duration of illness), compared to merely tracking temperature reduction.


Long-Term Studies and Follow-up Durations

The majority of regulatory evidence for Geralgine stems from research exploring short-term symptom changes, where studies monitored responses over defined time intervals, typically limiting follow-up to a single-dose assessment or repeated dosing over several days. Studies focusing on episodes where symptoms become more noticeable over a few days often provide limited insight into long-term changes. There is limited information for long-term outcomes, particularly for use during conditions characterized by chronic or non-episodic manifestations. Data show patterns related to mixed findings from observational studies exploring associations with long-term health outcomes, where differentiating between the influence of the medicine and underlying health issues remains a complexity. Consequently, long-term effects are not fully established from the available controlled research.

Key Studies & References

  1. Label: ACETAMINOPHEN tablet - DailyMed (Official NIH/FDA Labeling)
  2. WHO Model List of Essential Medicines - Section 2.1 Non-opioid analgesics

Frequently Asked Questions (FAQ)

Common questions about Geralgine (FAQ)


Q: How quickly should I expect Geralgine to start working?

Official pharmacokinetic data, which describes how the medicine moves through the body, indicates that the active ingredient typically reaches its highest level in the bloodstream within about one hour after being taken by mouth. This period generally aligns with the expected onset of the medicine's activity.


Q: How long does the effect of one dose of Geralgine last?

The therapeutic effect of a single dose is tied to the official dosing regimen. Regulatory information sets the minimum time interval between doses at typically four to six hours to maintain a measurable level of the active ingredient and limit the overall exposure risk.


Q: Does taking Geralgine make you feel drowsy or tired?

Clinical studies documented in official sources have reported fatigue (feeling very tired) as a common adverse event, occurring in about 1% to 10% of users. Official product information lists the reported side effects by frequency.


Q: Can Geralgine cause problems with sleep?

Official safety documentation includes insomnia, or difficulty sleeping, as a common psychiatric adverse event, reported in 1% to 10% of people in clinical trials. This is described within the official safety profile of the medicine.


Q: Is it safe to take Geralgine with birth control pills?

Official information notes that some oral contraceptives may slightly decrease or delay the effects of the active ingredient. However, regulatory interaction monographs generally describe concurrent use at usual therapeutic doses as carrying no significant additional risk.


Q: Can people with diabetes use Geralgine?

Official information describes that the active ingredient can interfere with the sensor readings of Continuous Glucose Monitors (CGMs), which are used to measure blood sugar. This interference could potentially lead to inaccurate glucose readings, which is a key caution for those using these devices.


Q: Is Geralgine safe for older adults (seniors)?

Regulatory documents advise that caution and assessment are necessary when the medicine is used in certain populations, such as the elderly or debilitated. These individuals, particularly if severe renal (kidney) or hepatic (liver) impairment is present, are factors that may require dosage adjustment or increased monitoring.


Q: What should I do if I accidentally take too much Geralgine?

In cases of suspected over-exposure to the active ingredient, regulatory guidance advises individuals to seek medical attention immediately, even if no symptoms are present. This is necessary as severe toxicity, such as liver damage, is the primary concern associated with over-exposure.


Q: Does Geralgine affect the results of blood work?

Official product labeling states that the active ingredient is known to potentially cause false positive results on some urine glucose tests. Furthermore, specialized laboratory blood tests are used to accurately measure the level of the active ingredient in the bloodstream if needed.


Q: What is the purpose of the different strengths of Geralgine tablets?

Different strengths of the tablets are manufactured to allow for flexible dosing based on the intensity of symptoms being managed. The availability of various strengths serves to support accurate calculation of the specific single and total daily dose limits required by regulatory guidelines.


Q: Does Geralgine have a cumulative effect over time?

Studies and official information indicate that the active ingredient has a half-life of approximately two to three hours in adults. Chronic, regular use at high doses may lead to the saturation of the body's major metabolic pathways, which affects how the medicine is processed over time.


Q: Is Geralgine known to be habit-forming or addictive?

According to official government classifications, the active ingredient is a non-opioid analgesic. It is not listed as a controlled substance under federal schedules, which indicates a lack of abuse or addiction potential.


Q: Is it common to have stomach upset when first starting Geralgine?

Regulatory documentation includes several gastrointestinal events in its adverse reaction profile. These include symptoms such as nausea, vomiting, abdominal pain, and diarrhea.


Q: Why does Geralgine sometimes feel different than [Similar Drug Name]?

Regulatory descriptions of the drug’s mechanism explain that its inhibitory action is limited in the peripheral tissues of the body. This focus on the central nervous system activity is what differentiates its effects from medicines that act primarily in the periphery.


Q: Does drinking coffee or caffeine affect Geralgine?

Official product information notes that the active ingredient is often combined with caffeine in certain over-the-counter formulations. This co-formulation is done because caffeine is used to enhance the pain-relieving effects of the analgesic component.


Q: Are there any foods or drinks I should avoid while using Geralgine?

Official patient warnings advise against consuming three or more alcoholic drinks daily while taking the medicine due to the increased risk of severe liver damage. There are no other general food or drink restrictions mentioned in the regulatory warnings.


Q: Can people with liver problems use Geralgine?

Regulatory documents state that use is contraindicated (prohibited) for patients with severe active liver disease or severe hepatic impairment. Individuals with mild to moderate hepatic impairment are also subject to cautionary use and mandatory dosage adjustments.


Q: Is Geralgine a controlled substance?

According to the regulatory classification, the active ingredient is a non-opioid analgesic. It is not listed as a controlled substance under federal law, indicating its status as a widely available medication.


Q: Why do some people say Geralgine helps with headaches?

Regulatory research evidence includes studies that have examined the drug’s effect in conditions associated with pain, such as headache. Its analgesic action is described as centrally mediated, meaning it works within the brain and spinal cord to modulate pain signals.


Q: Why do doctors check my medical history before prescribing Geralgine?

Regulatory guidance mandates that a patient’s medical history be assessed for risk factors that can increase the risk of severe toxicity. Key areas of assessment include the presence of severe liver or kidney disease and a history of chronic alcoholism.


Q: Can Geralgine be crushed or mixed with food?

Official information advises that certain formulations, such as those labeled as extended-release, must not be crushed or chewed. Modifying these types of tablets can alter the medicine's intended release pattern.


Q: Is it necessary to take Geralgine with a meal?

Official administration information states that oral forms of the medicine may be administered with or without food. Taking it with a meal is not strictly necessary for its absorption or effect.


Q: Is Geralgine a medication that needs to be taken daily?

The medicine is typically approved for use while symptoms last and is not necessarily a daily medication. Non-prescription use is subject to maximum duration limits (e.g., 10 days for pain, 3 days for fever).


Q: Are there specific vitamins or supplements that interact with Geralgine?

Regulatory warnings exist regarding the potential for the active ingredient to interfere with the sensor readings of some Continuous Glucose Monitors. Co-administration with other vitamins and supplements is not uniformly addressed in regulatory warnings.

How should Geralgine be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of Geralgine (Paracetamol) must comply strictly with the conditions detailed in official regulatory labeling to maintain product stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30°C (86°F).
Protection Keep dry and protect from direct light; avoid freezing.
Container Keep in the original container and ensure it is tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Geralgine must be discarded according to pharmaceutical waste protocols. Do not dispose of the medicine via wastewater or household trash. Instead, return the product to an authorized drug take-back location or pharmacy collection point as instructed by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Geralgine found in:

A-Z Index: